Sandra A Tsai1, Marcia L Stefanick, Randall S Stafford. 1. Program on Prevention Outcomes, Stanford Prevention Research Center, Stanford School of Medicine, Stanford, CA 94305-5411, USA. sandra.tsai@stanford.edu
Abstract
OBJECTIVE: The aim of this study was to evaluate recent trends and the adoption of practice recommendations for menopausal hormone therapy (MHT) use from 2001 to 2009 by formulation, dose, woman's age, and characteristics of physicians reporting MHT visits. METHODS: The IMS Health (Plymouth Meeting PA) National Disease and Therapeutic Index physician survey data from 2001 to 2009 were analyzed for visits in which MHT use was reported by US office-based physicians. Estimated national volume of visits for which MHT use was reported. RESULTS: MHT use declined each year since 2002. Systemic MHT use fell from 16.3 million (M) visits in 2001 to 6.1 M visits in 2009. Declines were greatest for women 60 years or older (64%) but were also substantial for women younger than 50 years (59%) and women 50 to 59 years old (60%). Women 60 years or older accounted for 37% of MHT use. Lower dose product use increased modestly, from 0.7 M (2001) to 1.3 M (2009), as did vaginal MHT use, from 1.8 M (2001) to 2.4 M (2009). Declines in continuing systemic MHT use (65%) were greater than for newly initiated MHT use (51%). Compared with other physicians, obstetrician/gynecologists changed their practices less, thereby increasing their overall share of total MHT visits from 72% (2001) to 82% (2009). CONCLUSIONS: Total MHT use has steadily declined. Increased use of lower dose and vaginal products reflects clinical recommendations. Uptake of these products, however, has been modest, and substantial use of MHT continues in older women.
OBJECTIVE: The aim of this study was to evaluate recent trends and the adoption of practice recommendations for menopausal hormone therapy (MHT) use from 2001 to 2009 by formulation, dose, woman's age, and characteristics of physicians reporting MHT visits. METHODS: The IMS Health (Plymouth Meeting PA) National Disease and Therapeutic Index physician survey data from 2001 to 2009 were analyzed for visits in which MHT use was reported by US office-based physicians. Estimated national volume of visits for which MHT use was reported. RESULTS: MHT use declined each year since 2002. Systemic MHT use fell from 16.3 million (M) visits in 2001 to 6.1 M visits in 2009. Declines were greatest for women 60 years or older (64%) but were also substantial for women younger than 50 years (59%) and women 50 to 59 years old (60%). Women 60 years or older accounted for 37% of MHT use. Lower dose product use increased modestly, from 0.7 M (2001) to 1.3 M (2009), as did vaginal MHT use, from 1.8 M (2001) to 2.4 M (2009). Declines in continuing systemic MHT use (65%) were greater than for newly initiated MHT use (51%). Compared with other physicians, obstetrician/gynecologists changed their practices less, thereby increasing their overall share of total MHT visits from 72% (2001) to 82% (2009). CONCLUSIONS: Total MHT use has steadily declined. Increased use of lower dose and vaginal products reflects clinical recommendations. Uptake of these products, however, has been modest, and substantial use of MHT continues in older women.
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Joann E Manson; Shari S Bassuk; S Mitchell Harman; Eliot A Brinton; Marcelle I Cedars; Rogerio Lobo; George R Merriam; Virginia M Miller; Frederick Naftolin; Nanette Santoro Journal: Menopause Date: 2006 Jan-Feb Impact factor: 2.953
Authors: Diana S M Buist; Katherine M Newton; Diana L Miglioretti; Kevin Beverly; Maureen T Connelly; Susan Andrade; Cynthia L Hartsfield; Feifei Wei; K Arnold Chan; Larry Kessler Journal: Obstet Gynecol Date: 2004-11 Impact factor: 7.661
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Ross L Prentice; Joann E Manson; Robert D Langer; Garnet L Anderson; Mary Pettinger; Rebecca D Jackson; Karen C Johnson; Lewis H Kuller; Dorothy S Lane; Jean Wactawski-Wende; Robert Brzyski; Matthew Allison; Judith Ockene; Gloria Sarto; Jacques E Rossouw Journal: Am J Epidemiol Date: 2009-05-25 Impact factor: 4.897
Authors: Katherine W Reeves; Mary Díaz Santana; JoAnn E Manson; Susan E Hankinson; R Thomas Zoeller; Carol Bigelow; Susan R Sturgeon; Donna Spiegelman; Lesley Tinker; Juhua Luo; Bertha Chen; Jaymie Meliker; Matthew R Bonner; Michele L Cote; Ting-Yuan David Cheng; Antonia M Calafat Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Robert A Wild; Chunyuan Wu; J D Curb; Lisa W Martin; Lawrence Phillips; Marcia Stefanick; Maurizio Trevisan; Joann E Manson Journal: Menopause Date: 2013-03 Impact factor: 2.953
Authors: Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506